Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Выбор эффективного диуретика для терапии хронической сердечной недостаточности на амбулаторном этапе: доводы в пользу торасемида
Выбор эффективного диуретика для терапии хронической сердечной недостаточности на амбулаторном этапе: доводы в пользу торасемида
Ларина В.Н. Выбор эффективного диуретика для терапии хронической сердечной недостаточности на амбулаторном этапе: доводы в пользу торасемида. Consilium Medicum. 2018; 20 (10): 29–35. DOI: 10.26442/2075-1753_2018.10.29-35
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье рассмотрены современные возможности лечения отечного синдрома при хронической сердечной недостаточности (ХСН). Уделяется внимание длительному поддерживающему лечению пациентов со II–IV функциональным классом ХСН. Подробно представлены возможности применения высокоселективного длительно действующего с высокой биодоступностью петлевого диуретика торасемида. Обсуждаются его диуретический эффект, антиальдостероновая, вазодилатирующая активность и антифибротическое действие. Анализируются клинические исследования, свидетельствующие об эффектах торасемида в отношении замедления миокардиального фиброза, улучшения функции левого желудочка, функционального класса ХСН, переносимости физической нагрузки, снижения частоты госпитализаций и смертности у пациентов с сердечной недостаточностью на фоне приема торасемида.
Ключевые слова: хроническая сердечная недостаточность, петлевые диуретики, торасемид, лечение.
Ключевые слова: хроническая сердечная недостаточность, петлевые диуретики, торасемид, лечение.
________________________________________________
Current trends and possibilities of edema syndrome treatment in chronic heart failure (CHF) are discussing in the article. The review is devoted to the persistent treatment of patients with II–IV functional class of CHF. Torasemide is a high-ceiling loop diuretic with a long half-life, long duration of action and high bioavailability. Additional actions such as antialdosterone and vasodilatation effects, and antifibrotic action are discussed. Clinical trials which are indicated that torasemide slows myocardial fibrosis, improves left ventricular function, improves functional class CHF, increases exercise tolerance and reduces mortality as well as the frequency and duration of heart failure-related hospitalization in patients with CHF are analyzed.
Key words: chronic heart failure, loop diuretics, torasemide, treatment.
Key words: chronic heart failure, loop diuretics, torasemide, treatment.
Полный текст
Список литературы
1. Мареев В.Ю., Фомин И.В., Агеев Ф.Т. и др. Клинические рекомендации ОССН – РКО – РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018; 58 (S6): 8–164. / Mareev V.Iu., Fomin I.V., Ageev F.T. i dr. Klinicheskie rekomendatsii OSSN – RKO – RNMOT. Serdechnaia nedostatochnost': khronicheskaia (KhSN) i ostraia dekompensirovannaia (ODSN). Diagnostika, profilaktika i lechenie. Kardiologiia. 2018; 58 (S6): 8–164. [in Russian]
2. Yancy C, Jessup M, Bozkurt B et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147–239.3. Mentz R, Kjeldsen K, Rossi G et al. Decongestion in acute hear failure. Eur J Heart Fail 2014; 16 (5): 471–82.
4. Peacock W, Costanzo M, De Marco T et al. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology 2009; 113: 12–9.
5. Neuberg G, Miller A, O’Connor C et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002; 144: 31–8. DOI: 10.1067/ mhj.2002.123144
6. Testani J, Brisco M, Turner J et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail 2014; 7: 261–70. DOI: 10.1161/ CIRCHEARTFAILURE.113.000895
7. Aronson D, Burger AJ. Diuretic response: clinical and hemodynamic predictors and relation to clinical outcome. J Card Fail 2016; 22: 193–200. DOI: 10.1016/j.cardfail.2015.07.006
8. Pham D, Grodin J. Dilemmas in the Dosing of Heart Failure Drugs: Titrating Diuretics in Chronic Heart Failure. Cardiac Failure Review 2017; 3 (2): 108–12. DOI: 10.15420/cfr.2017:10:1
9. Buggey J, Mentz R, Pitt B et al. A reappraisal of loop diuretic choice in heart failure patients. Am Heart J 2015; 169: 323–33.
10. Мареев В.Ю., Выгодин В.А., Беленков Ю.Н. Диуретическая терапия эффективными дозами пероральных диуретиков торасемида (диувера) и фуросемида в лечении больных с обострением хронической сердечной недостаточности (ДУЭЛЬ-ХСН). Сердечная недостаточность. 2011; 12 (3): 3–10. / Mareev V.Iu., Vygodin V.A., Belenkov Iu.N. Diureticheskaia terapiia effektivnymi dozami peroral'nykh diuretikov torasemida (diuvera) i furosemida v lechenii bol'nykh s obostreniem khronicheskoi serdechnoi nedostatochnosti (DUEL''-KhSN). Serdechnaia nedostatochnost'. 2011; 12 (3): 3–10. [in Russian]
11. Felker GM. Loop diuretics in heart failure. Heart Fail Rev 2012; 17 (2): 305–11.
12. DiNicolantonio J. Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiol 2012; 8 (5): 707–28.
13. Vormfelde S, Brockmoller J. The genetics of loop diuretic effects. Pharmacogenomics J 2012; 12: 45–53.
14. He B, Anderson M. Aldosterone and cardiovascular disease: the heart of the matter. Trends Endocrinol Metab 2013; 24: 21–30.
15. Мареев В.Ю. и др. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). ОССН, РКО. 2016. Сердечная недостаточность. 2017; 1 (18): 3–40. / Mareev V.Iu. i dr. Klinicheskie rekomendatsii. Khronicheskaia serdechnaia nedostatochnost' (KhSN). OSSN, RKO. 2016. Serdechnaia nedostatochnost'. 2017; 1 (18): 3–40. [in Russian]
16. Ponikowski P, Voors A, Anker S et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129–200. DOI: 10.1093/eurheartj/ehw128
17. Zannad F, McMurray J, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11–21.
18. Uchida T, Yamanaga K, Nishikawa M et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991; 205: 145–50.
19. Goodfriend T, Ball D, Oelkers W et al. Torsemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63: PL45–50.
20. Gravez B, Tarjus A, Jimenez-Canino R et al. The diuretic torasemide does not prevent aldosterone-mediated mineralocorticoid receptor activation in cardiomyocytes. PLoS One 2013; 8 (9): 1–8.
21. McCurley J, Hanlon S, Wei S et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004; 44: 1301–7.
22. Cosin J, Diez J et al. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4: 507–13.
23. Mentz R, Hasselblad V, DeVore A. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). Am J Cardiol 2016; 117: 404–11.
24. Piek A, de Boer R, Sillje H. The fibrosis-cell death axis in heart failure. Heart Fail Rev 2016; 21: 199–211.
25. Weber K, Sun Y, Bhattacharya S et al. Myofibroblast mediated mechanisms of pathological remodeling of the heart. Nat Rev Cardiol 2013; 10 (1): 15–26. DOI: 10.1038/ nrcardio.2012.158
26. Агеев Ф.Т., Жубрина Е.С., Гиляревский С.Р. и др. Сравнительная эффективность и безопасность длительного применения торасемида и фуросемида у больных с компенсированной сердечной недостаточностью. Влияние на маркеры фиброза миокарда. Сердечная недостаточность. 2013; 14 (2): 55–62. / Ageev F.T., Zhubrina E.S., Giliarevskii S.R. i dr. Sravnitel'naia effektivnost' i bezopasnost' dlitel'nogo primeneniia torasemida i furosemida u bol'nykh s kompensirovannoi serdechnoi nedostatochnost'iu. Vliianie na markery fibroza miokarda. Serdechnaia nedostatochnost'. 2013; 14 (2): 55–62. [in Russian]
27. Trippel T, Van Linthout S, Westermann D et al. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial). Eur J Heart Fail 2018; 20 (3): 460–70. DOI: 10.1002/ejhf.960
28. Lopez B, Querejeta R, Gonzalez A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43: 2028–35.
29. Tsutamoto T, Sakai H, Wada A et al. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2004; 44: 2252–3.
30. Lоpez B, Querejeta R, Gonzalez A et al. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009; 53 (2): 236–42. DOI: 10.1161/HYPERTENSIONAHA.108.125278
31. Group T. Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. Clin Ther 2011; 33: 1204–13.e3
32. Balsam P, Ozierański K, Tymińska A et al. The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure – TORNADO: a study protocol for a randomized controlled trial. Trials 2017; 18: 36. DOI 10.1186/s13063-016-1760-z
33. Барышникова Г.А., Чорбинская С.А. Диуретики в лечении артериальной гипертонии. Что нового? Consilium Medicum. 2017; 19 (1): 13–7. / Baryshnikova G.A., Chorbinskaia S.A. Diuretics in the treatment of arterial hypertension. What's new? Consilium Medicum. 2017; 19 (1): 13–7.
34. Трухан Д.И. Лечение хронической сердечной недостаточности и артериальной гипертензии: две цели и один препарат – торасемид. Consilium Medicum. 2017; 19 (10): 79–84. / Trukhan D.I. Treatment of chronic heart failure and arterial hypertension: two aims and one drug – torasemide. Consilium Medicum. 2017; 19 (10): 79–84.
________________________________________________
2. Yancy C, Jessup M, Bozkurt B et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147–239.
3. Mentz R, Kjeldsen K, Rossi G et al. Decongestion in acute hear failure. Eur J Heart Fail 2014; 16 (5): 471–82.
4. Peacock W, Costanzo M, De Marco T et al. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology 2009; 113: 12–9.
5. Neuberg G, Miller A, O’Connor C et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002; 144: 31–8. DOI: 10.1067/ mhj.2002.123144
6. Testani J, Brisco M, Turner J et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail 2014; 7: 261–70. DOI: 10.1161/ CIRCHEARTFAILURE.113.000895
7. Aronson D, Burger AJ. Diuretic response: clinical and hemodynamic predictors and relation to clinical outcome. J Card Fail 2016; 22: 193–200. DOI: 10.1016/j.cardfail.2015.07.006
8. Pham D, Grodin J. Dilemmas in the Dosing of Heart Failure Drugs: Titrating Diuretics in Chronic Heart Failure. Cardiac Failure Review 2017; 3 (2): 108–12. DOI: 10.15420/cfr.2017:10:1
9. Buggey J, Mentz R, Pitt B et al. A reappraisal of loop diuretic choice in heart failure patients. Am Heart J 2015; 169: 323–33.
10. Mareev V.Iu., Vygodin V.A., Belenkov Iu.N. Diureticheskaia terapiia effektivnymi dozami peroral'nykh diuretikov torasemida (diuvera) i furosemida v lechenii bol'nykh s obostreniem khronicheskoi serdechnoi nedostatochnosti (DUEL''-KhSN). Serdechnaia nedostatochnost'. 2011; 12 (3): 3–10. [in Russian]
11. Felker GM. Loop diuretics in heart failure. Heart Fail Rev 2012; 17 (2): 305–11.
12. DiNicolantonio J. Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiol 2012; 8 (5): 707–28.
13. Vormfelde S, Brockmoller J. The genetics of loop diuretic effects. Pharmacogenomics J 2012; 12: 45–53.
14. He B, Anderson M. Aldosterone and cardiovascular disease: the heart of the matter. Trends Endocrinol Metab 2013; 24: 21–30.
15. Mareev V.Iu. i dr. Klinicheskie rekomendatsii. Khronicheskaia serdechnaia nedostatochnost' (KhSN). OSSN, RKO. 2016. Serdechnaia nedostatochnost'. 2017; 1 (18): 3–40. [in Russian]
16. Ponikowski P, Voors A, Anker S et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129–200. DOI: 10.1093/eurheartj/ehw128
17. Zannad F, McMurray J, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11–21.
18. Uchida T, Yamanaga K, Nishikawa M et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991; 205: 145–50.
19. Goodfriend T, Ball D, Oelkers W et al. Torsemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63: PL45–50.
20. Gravez B, Tarjus A, Jimenez-Canino R et al. The diuretic torasemide does not prevent aldosterone-mediated mineralocorticoid receptor activation in cardiomyocytes. PLoS One 2013; 8 (9): 1–8.
21. McCurley J, Hanlon S, Wei S et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004; 44: 1301–7.
22. Cosin J, Diez J et al. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4: 507–13.
23. Mentz R, Hasselblad V, DeVore A. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). Am J Cardiol 2016; 117: 404–11.
24. Piek A, de Boer R, Sillje H. The fibrosis-cell death axis in heart failure. Heart Fail Rev 2016; 21: 199–211.
25. Weber K, Sun Y, Bhattacharya S et al. Myofibroblast mediated mechanisms of pathological remodeling of the heart. Nat Rev Cardiol 2013; 10 (1): 15–26. DOI: 10.1038/ nrcardio.2012.158
26. Ageev F.T., Zhubrina E.S., Giliarevskii S.R. i dr. Sravnitel'naia effektivnost' i bezopasnost' dlitel'nogo primeneniia torasemida i furosemida u bol'nykh s kompensirovannoi serdechnoi nedostatochnost'iu. Vliianie na markery fibroza miokarda. Serdechnaia nedostatochnost'. 2013; 14 (2): 55–62. [in Russian]
27. Trippel T, Van Linthout S, Westermann D et al. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial). Eur J Heart Fail 2018; 20 (3): 460–70. DOI: 10.1002/ejhf.960
28. Lopez B, Querejeta R, Gonzalez A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43: 2028–35.
29. Tsutamoto T, Sakai H, Wada A et al. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2004; 44: 2252–3.
30. Lоpez B, Querejeta R, Gonzalez A et al. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009; 53 (2): 236–42. DOI: 10.1161/HYPERTENSIONAHA.108.125278
31. Group T. Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. Clin Ther 2011; 33: 1204–13.e3
32. Balsam P, Ozierański K, Tymińska A et al. The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure – TORNADO: a study protocol for a randomized controlled trial. Trials 2017; 18: 36. DOI 10.1186/s13063-016-1760-z
33. Baryshnikova G.A., Chorbinskaia S.A. Diuretics in the treatment of arterial hypertension. What's new? Consilium Medicum. 2017; 19 (1): 13–7.
34. Trukhan D.I. Treatment of chronic heart failure and arterial hypertension: two aims and one drug – torasemide. Consilium Medicum. 2017; 19 (10): 79–84.
Авторы
В.Н.Ларина
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
larinav@mail.ru
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
larinav@mail.ru
________________________________________________
V.N.Larina
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
larinav@mail.ru
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
larinav@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.